A Phase I/II Open-label Study of EDP1503 Alone and in Combination With Pembrolizumab in Patients With Advanced Metastatic Colorectal Carcinoma, Triple-negative Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors
Phase of Trial: Phase I/II
Latest Information Update: 07 Feb 2019
At a glance
- Drugs EDP-1503 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Evelo Biosciences
- 04 Jan 2019 According to an Evelo Biosciences media release, initial data are expected in the first half of 2020.
- 04 Jan 2019 According to an Evelo Biosciences media release, first patient has been dosed.
- 02 Jan 2019 Status changed from not yet recruiting to recruiting.